Insilico Medicine was born at the Emerging Technology Centers in Baltimore in 2014 where founder and co-CEO Alex Zhavoronkov first began exploring combining bioinformatics with deep learning. He announced the company in 2015 at the NVIDIA GTC conference. The Company published our first proof-of-concept studies in 2016 in Nature Communications on a new method to uncover disease pathways using deep neural networks, the precursor of our powerful PandaOmics target discovery tool.

By 2019, we had published an experimental validation of our generative chemistry platform, Chemistry42, also in Nature, demonstrating that we could use our deep learning model to produce a de novo small molecule that was tested and validated in animal studies. We understood that we were onto something big – and we were determined to take our AI-developed drugs all the way to the clinic.

In 2021, Insilico brought on Dr. Feng Ren, Chief Scientific Officer, and co-CEO, to lead our clinical trial efforts, build a team of expert drug hunters, and take us to the finish line. Now, we have a lead AI-designed drug for idiopathic pulmonary fibrosis in Phase II trials with patients, five drugs at the clinical stage, and 31 drugs in our pipeline, including for cancer, fibrosis immunology, IBD, and COVID-19.

We’ve licensed a number of our therapeutic assets in strategic deals with Sanofi, Exelixis, MENARINI Group, Fosun Pharma and others. And we also license our AI platform software to many pharma and biotech companies and academic partners to enable faster global drug discovery and industry-scale validation.

Insilico Medicine is aligned over one mission: to develop very effective, very safe, life-saving therapeutics that target disease and aging simultaneously.

#ai #genai #drugdiscovery #anniversary #pharma #biotech #innovation #10years #clinicaltrials

свернуть